Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) treatment advances have improved survival, but unresectable metastatic CRC remains a significant challenge.
• Targeting mutated tumor suppressors and oncogenes has been difficult, limiting therapeutic development.
• The concept of synthetic lethality offers a novel strategy by targeting compensatory pathways essential for cancer cell survival.

Purpose of the Study:

• To review and discuss recent advances in cancer biology, focusing on synthetic lethality.
• To highlight the potential applications of these new therapeutic strategies in colorectal cancer treatment.

Main Methods:

• Review of current scientific literature on synthetic lethality and its application in cancer therapy.
• Discussion of specific examples, including poly-(ADP-ribose) polymerase 1 (PARP1) inhibitors and their relationship with DNA repair gene mutations.
• Exploration of targeting mechanisms for mutated tumor suppressors and oncogenes like RAS and Myc.

Main Results:

• Mutations in tumor suppressors (e.g., BRCA1/2) sensitize cancer cells to inhibitors of compensatory pathways (e.g., PARP1 inhibitors).
• This synthetic lethal approach enables the selective elimination of mutation-bearing cancer cells.
• Compounds targeting these vulnerabilities show high activity against various mutations, including those in DNA repair genes, RAS, and Myc.

Conclusions:

• Synthetic lethality represents a promising therapeutic paradigm for colorectal cancer, particularly for managing metastatic disease.
• Further research into novel synthetic lethal targets could lead to more effective and selective cancer treatments.
• This approach broadens the scope of 'druggable' targets by exploiting specific genetic vulnerabilities in cancer cells.